Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)

PFS was lower in this analysis compared to the PACIFIC trial; however, OS was similar, indicating comparable efficacy in a real-world setting among Brazilian patients with unresectable stage III NSCLC. No new safety concerns were identified.

Authors

Institutions

Publication Details

Journal
Jornal Brasileiro de Pneumologia
Published
2024-12-12
DOI
https://doi.org/10.36416/1806-3756/e20240228
Citations
1
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.42
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)

Caio de Almeida Monteiro, Mauro Zukin, Carlos Eduardo Baston Silva, Ana Caroline Zimmer Gelatti et al.
1 citations
Jornal Brasileiro de Pneumologia
Lung Cancer Diagnosis and Treatment
0.42
article

Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)

Caio de Almeida Monteiro, Mauro Zukin, Carlos Eduardo Baston Silva, Ana Caroline Zimmer Gelatti, Rafaela Gomes de Jesus, Ellias Magalhães e Abreu Lima, Williams Fernandes Barra, Yuri Cardoso Rodrigues Beckedorff Bittencourt, Gustavo Gössling, Victor José Timbó Gondim, Andrea Kazumi Shimada, Mônica Luciana Agostinho Padoan, Rosely Yamamura, W N William Júnior, Clarissa Mathias, Letícia de Jesus Rossato
article en
1 citations

Abstract

PFS was lower in this analysis compared to the PACIFIC trial; however, OS was similar, indicating comparable efficacy in a real-world setting among Brazilian patients with unresectable stage III NSCLC. No new safety concerns were identified.

Jornal Brasileiro de PneumologiaVol. 50(6)
Eastern Cooperative Oncology Group (US), Instituto de Ensino e Pesquisa Santa Casa (BR), Hospital de Câncer de Barretos (BR), D’Or Institute for Research and Education (BR), Hospital Santa Izabel (BR), Beneficência Portuguesa de São Paulo (BR), Fundação Instituto de Pesca do Estado do Rio de Janeiro (BR), Hospital Sírio-Libanês (BR), Pontifícia Universidade Católica do Rio Grande do Sul (BR), Universidade Federal do Pará (BR)
Openalex Percentile: Top 29%
Lung Cancer Diagnosis and Treatment
0.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.